Background: An increasing number of cell, tissue and organ transplant procedures take place each year in Canada, including procedures in clinics, physician and dental offices. The Public Health Agency of Canada (the Agency) is leading the development of a Cell, Tissue and Organ Surveillance System (CTOSS).
Introduction
An increasing number of cell, tissue and organ transplant procedures take place each year in Canada, including procedures in clinics, physician and dental offices (1) . Over 90,000 tissue allografts are distributed for transplantation, including musculoskeletal, vascular, skin, cardiac and corneal tissues (2) . Canadian Blood Services predicts that the need for organ transplants will increase significantly over the next two decades (3). The Public Health Agency of Canada (the Agency) is leading the development of a Cell, Tissue and Organ Surveillance System (CTOSS) that will aim to improve transplantation safety for Canadians by capturing and analyzing adverse event data and disseminating the resulting knowledge. Transplantation adverse event surveillance data is critical to our ability to improve patient safety through the development of appropriate programs and policies. Once fully developed, the system will collect data on moderate and severe adverse events in order to monitor trends in known and emerging risks and reduce the transmission of infectious diseases due to transplantation. The objective of this article is to summarize progress toward the development of the three component transplantation adverse event surveillance systems (4).
Methods
Minimum data elements and definitions of serious adverse events were developed in conjunction with definitions established in the European Union and the United States. For grading of severity related to the adverse event, the spectrum of nil, non-serious, serious, life-threatening and death were defined and applied to the case report. The grading system for imputability was applied to assess the probability that an adverse event in a recipient may be attributed to the process of donation or clinical application of the tissue applied. Data collection on adverse events related to human allograft tissue transplants began in April 2011 at pilot sites in Alberta, Ontario, Quebec, New Brunswick and Nova Scotia. The mechanisms used to gather transplantation adverse event reports vary among the participating pilot sites.
Results
By December 2013, eight tissue transplantation adverse events were reported and the majority involved corneal tissue ( Table 1) . There were five corneal tissue transplantation adverse events (AEs) reported to the Agency from the Alberta pilot site since April 1 of 2011 and one corneal tissue-related adverse event was reported to the Agency from the Nova Scotia pilot site in 2011. One cardiovascular tissue-related serious adverse event was reported to the Agency from the Quebec pilot site in 2012 as well as a corneal tissue-related adverse event in 2013. Overall, most surveillance sites delivered complete transplantation AE reports and annual reports. It generally took three to six months for the site and tissue establishment to conduct a complete investigation of a suspected transplantation AE. There were several factors which affected the reporting of transplantation AEs including the expertise and experience of the treating physician in the detection of transplantation AEs in recipients, the effectiveness of coordination between procurement organizations and the hospitals as well as the workload of the coordinators. 
Conclusion
Canada's Cell, Tissue and Organ Surveillance System increases our capacity to identify common adverse events associated with transplantation. Improved data collection and analysis will increase our understanding of transplantation adverse events and inform the development of strategies to prevent or minimize these events. The next step in developing CTOSS will be to establish data elements and definitions for the cell and organ transplant components of the system and expand the number of sites participating in CTOSS.
